Saturday 17 October 2026
Export NUVB’s income statement to Excel — free account
Nuvation Bio Inc.
NUVB Healthcare Biotechnology
Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024. In the quarter to June 2026, revenue grew 555.6%, EPS fell 5.88%, free cash flow grew 10.6% and total debt rose 372.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.45
0.30
−6.32%
Follow NUVB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
11.66 | 10.42 | 48.65 | 47.36 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(46.10) | 293.95 | (102.92) | (23.95) | |
P/B ratio |
7.80 | 4.66 | 10.01 | 3.89 | |
Price to Tangible BV |
8.13 | 4.83 | 10.39 | 4.03 | |
EV/Sales |
9.23 | 7.06 | 41.08 | 28.81 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(13.01) | (8.03) | (14.90) | (4.06) | |
EV/FCF |
(12.97) | (8.01) | (14.87) | (4.05) | |
Quick Ratio |
7.98 | 7.04 | 6.67 | 8.26 | |
Current Ratio |
8.37 | 7.44 | 6.95 | 8.48 | |
Net Debt/EBITDA |
8.22 | (101.44) | 14.36 | 8.93 | |
Debt/Assets |
33.38% | 8.70% | 8.90% | 8.76% | |
Debt/Equity |
0.98 | 0.17 | 0.17 | 0.16 | |
Asset Turnover |
0.24 | 0.26 | 0.11 | 0.05 | |
Operating CF/Net income |
0.68 | 0.94 | 0.81 | 0.95 | |
Capex/Depreciation |
(0.29) | (0.06) | (0.10) | (9.41) | |
Interest Coverage |
(7.55) | 0.58 | (5.10) | (8.64) | |
Research and Development Expense of Revenue |
96.76% | 42.11% | 81.92% | 219.86% | |
Selling, General and Administrative Expense of Revenue |
134.41% | 46.03% | 96.32% | 284.75% | |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
33.01% | 10.85% | 19.08% | 61.14% | |
Graham Net Nets |
0.12 | 0.20 | 0.09 | 0.24 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.65%) | (9.90%) | (6.70%) | (17.30%) | |
Free Cash Flow Yield |
(6.10%) | (8.46%) | (5.68%) | (15.02%) | |
Revenue per Share |
0.09 | 0.24 | 0.12 | 0.04 | |
Operating CF per Share |
(0.12) | 0.01 | (0.09) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.12) | 0.01 | (0.09) | (0.18) | |
Cash per Share |
1.90 | 1.54 | 1.55 | 1.60 | |
Shareholders Equity per Share |
0.73 | 0.92 | 0.90 | 0.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.73 | 0.92 | 0.90 | 0.95 | |
Free Cash Flow |
(43.22) | 5.02 | (29.82) | (60.90) | |
Working Capital |
639.68 | 512.01 | 489.29 | 509.40 | |
Capital Expenditures |
(0.25) | (0.05) | (0.09) | (8.01) | |
Net Current Asset Value |
235.79 | 300.85 | 282.41 | 301.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.61 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
19.20 | 15.72 | 17.83 | 9.05 | |
Average Payables |
17.25 | 16.49 | 7.91 | 13.87 | |
Average Inventory |
10.23 | 7.93 | — | — | |
Average Assets |
695.86 | 551.37 | 567.72 | 586.57 | |
Average Common Equity |
313.39 | 369.51 | 384.75 | 414.30 |
Columns are period end dates